Siolta Therapeutics is focused on developing live biotherapeutics that target the underlying mechanisms of diseases with significant unmet medical needs, particularly in the maternal-infant axis. Their proprietary Precision Symbiotics Platform™ integrates clinical data, bioinformatics, and advanced microbial science to create synergistic combinations of bacteria aimed at preventing and treating conditions such as atopic diseases, bacterial vaginosis (BV), and necrotizing enterocolitis (NEC). The company is advancing several products in its pipeline, including STMC-103H for atopic diseases, STMC-105 for recurrent BV, and STMC-106 for NEC, leveraging their deep understanding of human microbial ecology to address these health challenges.

The technologies employed by Siolta Therapeutics include a robust biobank for strain characterization, machine learning for knowledge discovery from clinical data, and in-house GMP manufacturing capabilities to ensure the quality and consistency of their biotherapeutics. Their approach emphasizes the importance of the gut microbiome in immune health and disease prevention, particularly in vulnerable populations such as infants. By focusing on the prevention of disease onset rather than merely treating symptoms, Siolta aims to revolutionize the management of allergic diseases and other conditions linked to microbiome dysbiosis, ultimately improving patient outcomes and reducing healthcare burdens.

United States

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.

Siolta Therapeutics

Company Details